- Home
- MOS vs EXAS Comparison
MOS vs EXAS Comparison
Compare MOS & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOS
- EXAS
- Stock Information
- Founded
- MOS 1987
- EXAS 1995
- Country
- MOS United States
- EXAS United States
- Employees
- MOS N/A
- EXAS N/A
- Industry
- MOS Agricultural Chemicals
- EXAS Medical Specialities
- Sector
- MOS Industrials
- EXAS Health Care
- Exchange
- MOS Nasdaq
- EXAS Nasdaq
- Market Cap
- MOS 10.6B
- EXAS 11.0B
- IPO Year
- MOS 2004
- EXAS N/A
- Fundamental
- Price
- MOS $25.61
- EXAS $65.83
- Analyst Decision
- MOS Buy
- EXAS Strong Buy
- Analyst Count
- MOS 14
- EXAS 21
- Target Price
- MOS $36.36
- EXAS $71.86
- AVG Volume (30 Days)
- MOS 6.5M
- EXAS 2.9M
- Earning Date
- MOS 11-04-2025
- EXAS 11-03-2025
- Dividend Yield
- MOS 3.44%
- EXAS N/A
- EPS Growth
- MOS 235.95
- EXAS N/A
- EPS
- MOS 3.87
- EXAS N/A
- Revenue
- MOS $11,894,600,000.00
- EXAS $3,082,033,000.00
- Revenue This Year
- MOS $16.57
- EXAS $16.68
- Revenue Next Year
- MOS $1.03
- EXAS $12.36
- P/E Ratio
- MOS $6.62
- EXAS N/A
- Revenue Growth
- MOS 3.83
- EXAS 14.47
- 52 Week Low
- MOS $22.36
- EXAS $38.81
- 52 Week High
- MOS $38.23
- EXAS $72.81
- Technical
- Relative Strength Index (RSI)
- MOS 24.30
- EXAS 61.04
- Support Level
- MOS $24.95
- EXAS $62.39
- Resistance Level
- MOS $27.85
- EXAS $72.81
- Average True Range (ATR)
- MOS 0.89
- EXAS 2.11
- MACD
- MOS -0.28
- EXAS -0.01
- Stochastic Oscillator
- MOS 11.66
- EXAS 30.90
About MOS Mosaic Company (The)
Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida, Brazil, and Peru and potash mines in Saskatchewan, New Mexico, and Brazil. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.